‘How I do’ CMR in DCM Dr Sanjay Prasad, Royal Brompton Hospital London, UK. For SCMR August 2006 This presentation is posted for members of scmr as an.

Slides:



Advertisements
Similar presentations
How we do….. CMR of the Coronaries Arteries Gavin Bainbridge, Sven Plein, John Greenwood CMR Clinical Research Group Leeds General Infirmary, UK
Advertisements

Advanced Heart Failure and the Role of Mechanical Circulatory Support
CMR of Non-ischemic Dilated and Restrictive Cardiomyopathies
Friedrich, J Am Coll Cardiol 2008 Tissue characterization of acute myocardial infarction and myocarditis by CMR Matthias G. Friedrich Stephenson Cardiovascular.
‘How I do’ the Evaluation of Pericardial Disease Brian J. Schietinger MD and Christopher M. Kramer MD For scmr.org From the University of Virginia This.
David A. Bluemke, M.D., Ph.D. Associate Professor, Clinical Director, MRI Departments of Radiology and Medicine Johns Hopkins University School of Medicine.
“How we do” CMR in acute myocardial infarction Derek J Hausenloy, Anna S Herrey, James C Moon UCLH Heart Hospital and The Hatter Institute, University.
‘How I do’ CMR in HCM Dr Sanjay Prasad, Royal Brompton Hospital London, UK. For SCMR August 2006 This presentation is posted for members of scmr as an.
Cyclosporine A reduces infarct size and has no detrimental effect of LV remodeling in STEMI patients Michel Ovize Cardiology Hospital and Inserm U886 Lyon.
‘How I do’ CMR in valvular heart disease Dr. Saul Myerson Clinical Lecturer in Cardiovascular Medicine For 02/2007 This presentation posted.
Heart Failure Whistle Stop Talks No 1 HFrEF and HFpEF Definitions for Diagnosis Susie Bowell BA Hons, RGN Heart Failure Specialist Nurse.
Dr. Meg-angela Christi M. Amores
Diagnostic Stress Testing
Ventricular Diastolic Filling and Function
Sylwia Heinze-Paluchowska Department of Magnetic Resonance Imaging (NZ56)
Case of the month Dr P Arumugam Consultant Nuclear Physician
The method for evaluating cardiac function by echocardiography
How I do CMR Myocardial Perfusion imaging SCMR Website 2006 Christopher Klassen MD, PHD University of Florida Health Science Center Dr. Norbert Wilke This.
Safety and feasibility of dobutamine stress cardiac magnetic resonance for cardiovascular assessment prior to renal transplantation Ripley DP 1,2, Gosling.
Guidelines for the Echocardiographic Assessment of
Epidemiology Incidence is unknown although some have estimated 1-2% of all patients presenting with “ACS” Mean age is and rarely has been reported.
Myocarditis: toward a better understanding for an improved diagnosis January 16 th, h-10h30.
Adult Echocardiography Lecture 10 Coronary Anatomy
“How I do” a CMR Volume study
Date of download: 5/31/2016 Copyright © 2016 McGraw-Hill Education. All rights reserved. Evaluation of the patient with known or suspected ischemic heart.
Contribution of Cardiac Magnetic Resonance to Differential Diagnosis of Suspected Acute Coronary Syndromes with No Culprit Lesion Dr. Giuseppe Gibelli,
A Typical Cardiac MRI Study
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Diagnostic Value of CMR in Patients With Biomarker-Positive.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Defining the Natural History of Uremic Cardiomyopathy.
MRI Detection of Sub Clinical Structural Cardiac Dysfunction in HIV Positive Men Dr Aisling Loy.
Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cardiac Magnetic Resonance Imaging for the Interventional.
Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Fibrosis With Mortality and Sudden.
Date of download: 11/11/2016 Copyright © The American College of Cardiology. All rights reserved. From: Targeted Left Ventricular Lead Placement to Guide.
Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: LV Noncompaction Cardiomyopathy or Just a Lot of.
“How we do….. CMR of the Coronaries Arteries”
“How we do” CMR in acute myocardial infarction
British Society of Cardiovascular Magnetic Resonance
Heart & Thalassemia . R.Miri,MD, Interventional Cardiologist.
‘How I do’ CMR in valvular heart disease
A 42 year old female presented with exertional dyspnoea
– р<0.05 between baseline
‘How I do’ CMR in DCM Dr Sanjay Prasad, Royal Brompton Hospital
‘How I do’ CMR in HCM Dr Sanjay Prasad, Royal Brompton Hospital
Ischemic cardiomyopathy
How I do CMR Myocardial Perfusion imaging
Utility of Cardiac MRI in Diagnosing Fabry’s Cardiomyopathy
                                                                                  Description of Clinical Presentation:
Tyumen Cardiology Center, Russia Tyumen
Myocarditis Associated With Campylobacter Enteritis: Report of Three Cases by Dries De Cock, Nick Hiltrop, Philippe Timmermans, Steven Dymarkowski, and.
Figure 10 Assessment of myocardial fibrosis
LVH & Heart murmur Murmur Increased w/ standing
Diastolic heart failure
Volume 10, Issue 1, Pages (January 2013)
CR 10: Myocarditis mimicking an acute coronary syndrome
Rodney H. Falk et al. JACC 2016;68:
“How I do” a CMR Volume study
Alexander Liu et al. JACC 2018;71:
Francisco Leyva et al. JACC 2017;70:
Volume 154, Issue 4, Pages e101-e105 (October 2018)
Alan G. Japp et al. JACC 2016;67: Differentiation of Athlete’s Heart From Early DCM by Myocardial Deformation Imaging Two-dimensional speckle.
Myocardial Perfusion, Scarring, and Function in Anomalous Left Coronary Artery From the Pulmonary Artery Syndrome: A Long-Term Analysis Using Magnetic.
Nat. Rev. Cardiol. doi: /nrcardio
Early and late results of left ventricular reconstruction in thin-walled chambers: Is this our patient population?  Gerald D. Buckberg, MD  The Journal.
Michela Brambatti et al. JACC 2017;70:
Volume 69, Issue 10, Pages (May 2006)
LVH & Heart murmur Murmur Increased w/ standing
Ingrid Kindermann et al. JACC 2012;59:
Canadian Society for Cardiovascular Magnetic Resonance (CanSCMR) Recommendations for Cardiovascular Magnetic Resonance Image Analysis and Reporting 
Fig. 7. T1 mapping in dilated cardiomyopathy (DCM)
Figure 1 Flowchart illustrating numbers of cases evaluated at each stage of study. SADS, sudden arrhythmic death ... Figure 1 Flowchart illustrating numbers.
Presentation transcript:

‘How I do’ CMR in DCM Dr Sanjay Prasad, Royal Brompton Hospital London, UK. For SCMR August 2006 This presentation is posted for members of scmr as an educational guide – it represents the views and practices of the author, and not necessarily those of SCMR.

Cine

Dilated Cardiomyopathy Unexplained dilatation and impaired contractile performance of the left ventricle in the absence of significant coronary artery disease Unexplained dilatation and impaired contractile performance of the left ventricle in the absence of significant coronary artery disease Prevalence – 38/ Prevalence – 38/ Variable onset Variable onset A familial basis is seen in around 15% of patients A familial basis is seen in around 15% of patients

Dilated Cardiomyopathy: Causes Idiopathic — 50 % Idiopathic — 50 % Myocarditis — 9 % Myocarditis — 9 % Infiltrative disease — 5 % Infiltrative disease — 5 % Peripartum cardiomyopathy — 4 % Peripartum cardiomyopathy — 4 % Hypertension — 4 % Hypertension — 4 % HIV infection — 4 % HIV infection — 4 % Connective tissue disease — 3 % Connective tissue disease — 3 % Other — 10 percent Other — 10 percent Felker et al, NEJM 2000

DCM: Diagnosis Often late presentation Often late presentation Annual mortality ~4% (>SCD) Annual mortality ~4% (>SCD) Opportunity for detection at an early/preclinical stage Opportunity for detection at an early/preclinical stage

CMR Evaluation of DCM The first important aspect is determining LV and RV volumes, ejection fractions and mass The first important aspect is determining LV and RV volumes, ejection fractions and mass We recommend the modified Simpson’s method rather than biplanar assessment since it makes no assumptions on cardiac morphology and is both more accurate and reproducible. We recommend the modified Simpson’s method rather than biplanar assessment since it makes no assumptions on cardiac morphology and is both more accurate and reproducible. After piloting the 4ch and VLA views, retrospectively gated gradient echo cine slices are taken from the base to apex After piloting the 4ch and VLA views, retrospectively gated gradient echo cine slices are taken from the base to apex Typically 7mm slices with a 3mm gap. Typically 7mm slices with a 3mm gap. Usually myocardial coverage is achieved in 9-10 slices Usually myocardial coverage is achieved in 9-10 slices

CMR Quantification See the presentation ‘how I do’ LV volumes Downloadable from

T2 Imaging In patients with an acute presentation of DCM, T2-weighted imaging is recommended to look for evidence of active inflammation/oedema. In patients with an acute presentation of DCM, T2-weighted imaging is recommended to look for evidence of active inflammation/oedema. The most likely cause for increased signal in the absence of infarction will be due to myocarditis The most likely cause for increased signal in the absence of infarction will be due to myocarditis Occasionally other conditions such as sarcoidosis may also manifest in this way. Occasionally other conditions such as sarcoidosis may also manifest in this way.

T2 Imaging Patient with a dilated LV and evidence of increased mid-wall/subepicardial signal on T2-weighted images in the anterolateral wall. The underlying diagnosis was DCM post-myocarditis.

T2 Imaging If the T2-weighted triple-inversion recovery sequence is used, typical sequence parameters are :- If the T2-weighted triple-inversion recovery sequence is used, typical sequence parameters are :- Slice thickness of 8mm Slice thickness of 8mm Surface and body coils Surface and body coils TR – 2x RR TR – 2x RR TE- 65ms TE- 65ms TI – 170ms TI – 170ms Images are taken in the VLA, 4ch view, plus a full SA stack Images are taken in the VLA, 4ch view, plus a full SA stack

Assessment of Fibrosis The presence of replacement fibrosis can be detected using the inversion recovery late enhancement technique following gadolinium-DTPA administration. The presence of replacement fibrosis can be detected using the inversion recovery late enhancement technique following gadolinium-DTPA administration. In several recent studies, about 60% of patients with DCM showed no detectable fibrosis. In several recent studies, about 60% of patients with DCM showed no detectable fibrosis. 30% showed mid-wall enhancement that correlates with fibrosis on histology. 30% showed mid-wall enhancement that correlates with fibrosis on histology. 10% showed a typical pattern of infarction with subendocardial rather than mid-wall enhancement. In the presence of normal coronaries, this is likely to represent recannalisation, an embolic episode or coronary spasm. 10% showed a typical pattern of infarction with subendocardial rather than mid-wall enhancement. In the presence of normal coronaries, this is likely to represent recannalisation, an embolic episode or coronary spasm. McCrohon J et al, Circulation 2003

Detection of Fibrosis: Inversion Recovery Sequence Dosage of Gd-DTPA: mmol/kg Dosage of Gd-DTPA: mmol/kg At 0.1mmol/kg, images are usually acquired after about 5 minutes with a TI starting at ~340ms (every other heart beat). At 0.1mmol/kg, images are usually acquired after about 5 minutes with a TI starting at ~340ms (every other heart beat). At 0.2 mmol/kg, scans are acquired after about 15 minutes with a TI starting at ~250ms. At 0.2 mmol/kg, scans are acquired after about 15 minutes with a TI starting at ~250ms.

Detection of Fibrosis: Inversion Recovery Sequence Tips to confirm mid-wall fibrosis and ensure that artefact is not being detected are:- Tips to confirm mid-wall fibrosis and ensure that artefact is not being detected are:- 1. Phase swap each slice 2. If mid-wall enhancement is seen, ensure that the TI is optimal and if need be, repeat the slice with a different TI 3. Cross-cut through any areas of suspected mid-wall enhancement 4. If subendocardial enhancement is seen, reconsider the diagnosis or assess if this reflects ‘bystander’ coronary disease 5. It is normal to see some fibrosis around the LVOT and at the RV/LV septal insertion points

Assessment of Fibrosis In this example, no late enhancement is seen reflecting the absence of detectable fibrosis

In this patient, there is evidence of mid-wall fibrosis (arrows) Assessment of Fibrosis

-It may be prognostically significant -It may indicate aetiology of LVF -It may indicate response to treatment -(beta-blockers/device therapy) Why assess fibrosis Assomull et al, JACC 2006 (In press)

Assessment of Fibrosis Although the prescan diagnosis was of DCM (normal coronary angiogram), the CMR study shows extensive subendocardial enhancement reflecting an ischaemic aetiology Although the prescan diagnosis was of DCM (normal coronary angiogram), the CMR study shows extensive subendocardial enhancement reflecting an ischaemic aetiology

Follow-Up This will be clinically determined This will be clinically determined In a stable patient where the question is of determining reverse remodelling, a reasonable interscan interval would be about 12 months In a stable patient where the question is of determining reverse remodelling, a reasonable interscan interval would be about 12 months